Home > Healthcare > Biotechnology > Biotechnology R&D > Mesenchymal Stem Cells Market

Mesenchymal Stem Cells Market Trends

Report ID: GMI6555
Published Date: Aug 2023
Report Format: PDF

Download Free Sample

Mesenchymal Stem Cells Market Trends

Rising prevalence of chronic diseases such as diabetes, cancer, cardiovascular ailments, and degenerative disorders have created significant demand for transformative therapies. Mesenchymal stem cells offers regenerative properties and immunomodulatory capabilities that position them as a promising candidates for treating chronic conditions by promoting tissue repair and modulating inflammatory responses. For instance, in 2020, according to the American Cancer Society, over 1.8 million new cancer cases were reported, and 606,520 people died of cancer in U.S. Similarly, in 2022, according to Parkinson’s Foundation, over 10 million people are suffering from Parkinson’s disease globally.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for mesenchymal stem cells accounted for USD 3 billion in 2022 and is estimated to grow at 12.8% CAGR from 2023 to 2032, backed by the rising prevalence of chronic diseases such as cancer, autoimmune disease, diabetes, and others.

The products segment accounted for 76.8% of the market share in 2022 and is projected to witness robust growth through 2032. Products like kits and reagents designed for mesenchymal stem cells research streamline experimental processes, ensuring accuracy and reproducibility.

North America market accounted for 42.4% revenu share in 2022 and is anticipated to grow at considerable growth rate owing to robust research infrastructure coupled with a strong emphasis on medical innovation, leading to a thriving MSC-related advancements.

Thermo Fisher Scientific, Inc., Cell Applications, Inc., Cyagen Biosciences, Lonza, PromoCell GmbH among others.